| Percentage of Positive Cells | Staining Intensity | ||||||
---|---|---|---|---|---|---|---|---|
 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
 | N | N | N | N | N | N | N | N |
 | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
Age | Â | Â | Â | Â | Â | Â | Â | Â |
   ≤45 year | 11 | 38 | 20 | 30 | 5 | 33 | 35 | 26 |
 | (11.1) | (38.4) | (20.2) | (30.3) | (5.1) | (33.3) | (35.4) | (26.3) |
   >45 year | 16 | 40 | 21 | 64 | 5 | 46 | 54 | 36 |
 | (11.3) | (28.4) | (14.9) | (45.4) | (3.5) | (32.6) | (38.3) | (25.5) |
T Classification | Â | Â | Â | Â | Â | Â | Â | Â |
   T1 | 8 | 21 | 0 | 16 | 5 | 23 | 8 | 9 |
 | (17.8) | (46.7) | (0.0) | (35.6) | (11.1) | (51.1) | (17.8) | (20.0) |
   T2 | 16 | 36 | 23 | 60 | 4 | 45 | 52 | 34 |
 | (11.9) | (26.7) | (17.0) | (44.4) | (3.0) | (33.3) | (38.5) | (25.2) |
   T3 | 4 | 16 | 14 | 18 | 2 | 9 | 26 | 15 |
 | (7.7) | (30.8) | (26.9) | (34.6) | (3.8) | (17.3) | (50.0) | (28.8) |
   T4 | 0 | 7 | 5 | 8 | 0 | 5 | 9 | 6 |
 | (0.0) | (35.0) | (25.0) | (40.0) | (0.0) | (25.0) | (45.0) | (30.0) |
N Classification | Â | Â | Â | Â | Â | Â | Â | Â |
   N0 | 18 | 35 | 6 | 31 | 6 | 44 | 24 | 16 |
 | (20.0) | (38.9) | (6.7) | (34.4) | (6.7) | (48.9) | (26.7) | (17.8) |
   N1 | 10 | 35 | 28 | 59 | 5 | 30 | 57 | 40 |
 | (7.6) | (26.5) | (21.2) | (44.7) | (3.8) | (22.7) | (43.2) | (30.3) |
   N2 | 0 | 6 | 6 | 10 | 0 | 5 | 10 | 7 |
 | (0.0) | (27.3) | (27.3) | (45.5) | (0.0) | (22.7) | (45.5) | (31.8) |
   N3 | 0 | 4 | 2 | 2 | 0 | 3 | 4 | 1 |
 | (0.0) | (50.0) | (25.0) | (25.0) | (0.0) | (37.5) | (50.0) | (12.5) |
M Classification | Â | Â | Â | Â | Â | Â | Â | Â |
   M0 | 27 | 67 | 30 | 83 | 10 | 72 | 79 | 46 |
 | (13.0) | (32.4) | (14.5) | (40.1) | (4.8) | (34.8) | (38.2) | (22.2) |
   M1 | 1 | 13 | 12 | 19 | 1 | 10 | 16 | 18 |
 | (2.2) | (28.9) | (26.7) | (42.2) | (2.2) | (22.2) | (35.6) | (40.0) |
Clinical Stage | Â | Â | Â | Â | Â | Â | Â | Â |
   I | 3 | 14 | 0 | 6 | 2 | 16 | 2 | 3 |
 | (13.0) | (60.9) | (0.0) | (26.1) | (8.7) | (69.6) | (8.7) | (13.0) |
   II | 21 | 33 | 6 | 34 | 7 | 41 | 30 | 16 |
 | (22.3) | (35.1) | (6.4) | (36.2) | (7.4) | (43.6) | (31.9) | (17.0) |
   III | 3 | 20 | 24 | 43 | 1 | 15 | 47 | 17 |
 | (3.3) | (22.2) | (26.7) | (47.8) | (1.1) | (16.7) | (52.2) | (30.0) |
   IV | 1 | 13 | 12 | 19 | 1 | 10 | 16 | 18 |
 | (2.2) | (28.9) | (26.7) | (42.2) | (2.2) | (22.2) | (35.6) | (40.0) |
ER Presence | Â | Â | Â | Â | Â | Â | Â | Â |
   Negative | 19 | 37 | 23 | 42 | 8 | 39 | 42 | 32 |
 | (15.7) | (30.6) | (19.0) | (32.7) | (6.6) | (32.2) | (34.7) | (26.4) |
   Positive | 9 | 43 | 19 | 60 | 3 | 43 | 53 | 32 |
 | (6.9) | (32.8) | (14.5) | (45.8) | (2.3) | (32.8) | (40.5) | (24.4) |
PR Presence | Â | Â | Â | Â | Â | Â | Â | Â |
   Negative | 16 | 30 | 23 | 38 | 5 | 33 | 40 | 29 |
 | (15.0) | (28.0) | (21.5) | (35.5) | (4.7) | (30.8) | (37.4) | (27.1) |
   Positive | 12 | 50 | 19 | 64 | 6 | 49 | 55 | 35 |
 | (8.3) | (34.5) | (13.1) | (44.1) | (4.1) | (33.8) | (37.9) | (24.1) |
HER-2 Presence | Â | Â | Â | Â | Â | Â | Â | Â |
   Negative | 9 | 12 | 8 | 22 | 4 | 17 | 14 | 16 |
 | (17.6) | (23.5) | (15.7) | (43.1) | (7.8) | (3.3) | (27.5) | (31.4) |
   Positive | 12 | 30 | 16 | 50 | 5 | 34 | 38 | 31 |
 | (11.1) | (27.8) | (14.8) | (46.3) | (4.6) | (31.5) | (35.2) | (28.7) |